Funding for this research was provided by:
Text and Data Mining valid from 2019-01-07
Received: 11 October 2017
Accepted: 13 December 2018
First Online: 7 January 2019
: The study protocol and patient informed consent form were approved by the institutional review board or independent ethics committee at each centre. The institutional review boards or independent ethics committees included Eticka komise, Multicenticka eticka komise Fakultni nemocnice Olomouc, Eticka komise Fakultni nemocnice Na Bulovce, Eticka komise, and Masarykuv onkologicky usta y (Czech Republic); Ethikkommission des Fachbereichs Medizin der Johann Wolfgang (Germany); Yamagata University Hospital IRB, Kinki University Hospital IRB, Keio University Hospital IRB, Tokushima University Hospital IRB, Kyushu University Hospital IRB, Sapporo Medical University Hospital IRB, Hokkaido University Hospital IRB, Chiba Cancer Centre IRB, Hamamatsu University School of Medicine, University Hospital IRB, Kobe University Hospital IRB, Nagoya University Hospital IRB, Akita University Hospital IRB, Japanese Foundation For Cancer Research Cancer Institute Hospital IRB, National Cancer Centre IRB, and Nagasaki University Hospital IRB (Japan); Ethics Council at the Ministry of Healthcare and Social Development of Russian Federation, Local Ethics Committee at Russian Research Centre of Roentgenology and Radiology, Ethics Committee, Russian Oncological Research Centre n.a. Blokhin RAMS, Ethics Committee at Samara Regional Clinical Oncology Dispensary, Local ethical committee Institution of Russian Academy of Medical Sciences Medical Radiology Research Centre of RAMS, Ethics Committee Leningrad Regional Oncology Dispensary, Ethics Committee at the City Clinical Oncology Dispensary of Saint- Petersburg, and Ethics Committee at the Federal Service on Surveillance in Healthcare and Social Development (Russian Federation); CEIC AREA 5-Hospital Universitario La Paz Ethics Committee of Clinic Hospital General, Hospital Gregorio Marañon Comite Etico de Investigacion Clinica, and Hospital Universitario La Paz Ethics Committee of Clinic Investigation (Spain); Nebraska Methodist Hospital Institutional Review Board, Office for Human Research Studies Dana Farber Cancer Institute, Cleveland Clinic Institutional Review Board, University of Nebraska Medical Centre Institutional Review Board, The Johns Hopkins Medicine Institutional Review Board, Quorurn Review, Schulman Associates Institutional Review Board, Inc., IUPUI Institutional Review Board, Indiana University Institutional Review Board, Western Institutional Review Board, Washington University School of Medicine Human Research Protection Office (IRB), University of Texas M.D. Anderson Cancer Centre Surveillance Committee FWA-363, Oregon Health and Science University Research Integrity Office (ORIO) Institutional Review Board, and University of Cincinnati Institutional Review Board (USA). Written informed consent was obtained from each patient.
: Not applicable since the manuscript does not contain any individual patient data.
: YT has received research funding from Pfizer, Ono, Takeda and Astellas, and honoraria from Pfizer, Novartis, Ono, Astellas and Bristol-Myers Squibb. HU has received research funding from Pfizer and Novartis, and honoraria from Pfizer, Bayer, Novartis, Ono and Bristol-Myers Squibb. MO has received research funding and honoraria from Pfizer, Novartis and Ono, and honoraria from Bayer. NS has received research funding from Pfizer, Ono and Astellas, and honoraria from Pfizer, Bayer, Novartis and GlaxoSmithKline. TH has received research funding and honoraria from Pfizer, Novartis and Bayer. YF, YK, and YU are employed by Pfizer R&D Japan and YU owns stock in Pfizer. AHB is employed by and owns stock in Pfizer. BIR has served as a consultant for and received research funding from Pfizer.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.